Fotios Kaltsas
Chronic Kidney Disease is a significant complication in diabetic patients, often leading to end-stage renal disease. Recent studies have identified Sodium-Glucose Cotransporter-2 (SGLT2) inhibitors as an effective therapeutic class for not only managing hyperglycemia but also for slowing the progression of CKD in diabetic patients. This review discusses the mechanisms by which SGLT2 inhibitors exert renoprotective effects, examines clinical trial data, and explores the implications for treatment strategies in diabetic nephropathy. Our findings suggest that SGLT2 inhibitors significantly reduce the risk of CKD progression, providing a promising avenue for improving long-term renal outcomes in diabetic patients.
Partagez cet article
English 
Spanish 
Chinese 
Russian 
German 
Japanese 
Portuguese 
Hindi 